Cue Biopharma, Inc. will effect a 1-for-30 reverse stock split of its common stock effective April 23, 2026, to regain compliance with Nasdaq's minimum bid price requirement.
Key takeaways
A 1-for-30 reverse stock split of common stock will become effective at 5:00 p.m. ET on April 23, 2026.
The reverse split is intended to bring the company into compliance with Nasdaq Capital Market's minimum bid price requirement.
No fractional shares will be issued; stockholders entitled to fractional shares will receive a cash payment in lieu.
The reverse split will proportionally adjust outstanding stock options, warrants, and shares available under equity incentive plans.
The common stock will begin trading on a post-split basis at market open on April 24, 2026 under the existing symbol 'CUE' with a new CUSIP number 22978P205.
The reverse split will not change the number of authorized shares of common stock or its par value of $0.001 per share.